Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | OSBP | P22059 | 1/20 | 0.64 |
| ▸ | RORC | P51449 | 1/20 | 0.64 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.64 |
| ▸ | POLA1 | P09884 | 1/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.58 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7741660 | 0.89 | USP2 (0.70) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL4284415 | 0.89 | USP2 (0.69) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL1243707 | 0.88 | USP2 (0.66) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL10929495 | 0.87 | USP2 (0.65) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL10929500 | 0.87 | USP2 (0.65) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL10930823 | 0.87 | USP2 (0.65) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL3977940 | 0.86 | CYP46A1 (0.64) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL8605712 | 0.86 | CYP46A1 (0.64) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL29081074 | 0.86 | CYP46A1 (0.68) | CYP46A1USP2LMNAABCB1OSBP | |
| SCHEMBL29081076 | 0.86 | CYP46A1 (0.68) | CYP46A1USP2LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11005742-A | — | — | None | — | — | JP | disclosed |
| US-11384115-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210147469-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-05-20 | — | — | US | disclosed |
| US-10844089-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190169225-A1 | Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2019-06-06 | — | — | US | disclosed |
| US-20180346509-A9 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2018-12-06 | — | — | US | disclosed |
| US-10144759-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-12-04 | — | — | US | disclosed |
| US-20160264615-A1 | Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis | UNIV VIRGINIA COMMONWEALTH (US) | 2016-09-15 | — | — | US | disclosed |
| US-9321802-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| US-20130143854-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| US-8399441-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100273761-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2010-10-28 | — | — | US | disclosed |
| US-20070275939-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF CHOLESTEROL HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, AND ATHEROSCLEROSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2007-11-29 | — | — | US | disclosed |
| WO-2006047022-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF CHOLESTEROL HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, AND ATHEROSCLEROSIS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2006-05-04 | — | — | WO | disclosed |
| JP-H115742-A | EXTERNAL PREPARATION CONTAINING CHOLESTEROL SULFATE | SHISEIDO CO LTD | 1999-01-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147469-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 2073/4885LMNA 3048/4885 |
| US-20160264615-A1 | Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 2073/4885LMNA 3048/4885 |
| US-20190169225-A1 | Nuclear Sulfated Oxysterol, Potent Regulator of Lipid Homeostasis, for Therapy of Hypercholesterolemia, Hypertriglycerides, Fatty Liver Diseases, and Atherosclerosis | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 2073/4885LMNA 3048/4885 |
| US-10844089-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 2073/4885LMNA 3048/4885 |
| US-11384115-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 2073/4885LMNA 3048/4885 |
| US-20070275939-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF CHOLESTEROL HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, AND ATHEROSCLEROSIS | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 1762/4885LMNA 2343/4885 |
| US-20100273761-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 2073/4885LMNA 3048/4885 |
| US-20130143854-A1 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 2073/4885LMNA 3048/4885 |
| US-20180346509-A9 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 2073/4885LMNA 3048/4885 |
| US-10144759-B2 | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis | NR1H3, NR1H2, SREBF1 | CYP46A1 5/4885USP2 2073/4885LMNA 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.